DS Healthcare Announces Results from New Clinical Study

DS Healthcare Announces Results from New Clinical Study

Spectral.DNC-S containing a new compound from pine showed efficacy in the
treatment of thinning hair

Pompano Beach, July 17, 2013 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc.
(NASDAQ:DSKX), a leading developer of personal care products, announced today
clinical results of a study showing that its Spectral.DNC-S containing a
compound sourced as a byproduct of pine production is effective in the
promotion of healthy hair and in the cessation of thinning hair in males.

Spectral.DNC-S addresses the $3.5 billion spent per year by Americans
attempting to treat their hair loss. Spectral.DNC-S is a completely new
innovation for the treatment of thinning hair. After several years of
exhaustive research, DS Laboratories has discovered a compound from a natural
source which mimic and exceed the activity of pharmaceutical treatments but
with greatly reduced side effects. This compound, sourced from pine bark, is
believed to act by opening ion channels in cells. It is DS Healthcare's most
potent and advanced formulation to date and provides an entirely new mechanism
of action.

The double-blind trial was conducted at Miami Dade Medical Center in Miami,
Florida. The subjects were between the ages of 25 and 55 years and had been
experiencing active thinning hair. Clinical assessment of scalps of volunteers
showed that 85% of subjects had an increase in hair density and 17% had a
dramatic improvement. 11% of subjects had no response.

"These clinical results provide further evidence that there are many variables
involved in overall hair and scalp health, and this in turn forms the
cornerstone of our multivariate approach to therapy. We believe this product
line holds great promise for broad commercial success in global markets where
we currently have distribution channels," stated DS Healthcare Group President
and CEO, Daniel Khesin. 

About DS Healthcare Group

DS Healthcare Group, Inc. leads in the development of biotechnology for
topical, and nutritional therapies. It markets through online and specialty
retailers, distributors, cosmetics wholesalers and salons. Its brands include
DS Laboratories (www.DSLaboratories.com), Sigma Skin (www.SigmaSkin.com),
Polaris Research Laboratories (www.PolarisReserachLabs.com) and Pure Guild
(www.ThePureGuild.com).

Forward-Looking Statements:

Except for statements of historical fact, the matters discussed in this press
release are forward-looking and made pursuant to the Safe Harbor provisions of
the Private Securities Litigation Reform Act of 1995. "Forward-looking
statements" describe future expectations, plans, results, or strategies and
are generally preceded by words such as "future," "plan" or "planned,"
"expects," or "projected." These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many of which
are beyond the company's control that may cause actual results to differ
materially from stated expectations. These risk factors include, among others,
limited operating history, difficulty in developing and marketing products,
intense competition and additional risks factors as discussed in reports filed
by the company with the Securities and Exchange Commission, which are
available at http://www.sec.gov.

CONTACT: Contact:
         Laurel Moody
         Corporate Profile
         1.646.810.0608
 
Press spacebar to pause and continue. Press esc to stop.